En stigning i serumeksponering for nilotinib mellem den første dosis og steady state var 2 gange for en daglig dosering og 3, 8 gange for to daglige doseringer.
An increase in serum exposure to nilotinib between the first dose and steady state was approximately 2-fold for daily dosing and 3.8-fold for twice-daily dosing.